Datavant

factnew Inovalon is not a captive Datavant tokenization vendor-dependency: Inovalon runs its own Preferred Data Partner Program (Oct 2023) with HealthVerity — a Datavant competitor — as its first/named RWE-linkage partner, and markets its own patient-tokenization/PPRL capability for connecting RCT and real-world data.

factnew Datavant's core model is connect, not own: it de-identifies and links disparate datasets via encrypted interoperable tokens and historically positioned itself as a neutral utility that 'does not monetize data, does not perform analytics, and does not have favorite partners' — it links the underlying claims/EHR/genomics data that its 350+ partners own rather than owning that data itself.

factnew Datavant reported more than $1 billion in 2025 revenue and described itself as profitable and cash-flow positive, positioning it to fund acquisitions from cash on hand — but this is COMPANY-REPORTED (leadership statements to trade press), not audited or independently confirmed.

factnew Datavant's network (company-reported) spans 80,000+ hospitals and clinics, more than 75% of the 100 largest US health systems, 100% of US payers, and 350+ real-world data partners, enabling 60M+ healthcare records to move across the ecosystem — the largest and most diverse US health-data network.

factnew Datavant completed its acquisition of Aetion on 2025-07-11; Aetion now operates as 'a Datavant Company' inside Datavant's Life Sciences business, giving the combined entity an end-to-end RWE offering (tokenization + linkage + Aetion's regulatory-grade study analytics) across 300+ data partners.

factnew Aetion's regulatory-grade credibility — now Datavant's — is independently substantiated: the FDA-funded RCT-DUPLICATE program (FDA + Brigham and Women's/Harvard + Aetion) replicated trial results with RWE, with 9 of 10 RWE studies meeting at least two of three pre-set agreement metrics, published in Circulation, and Aetion explicitly markets RWE 'accepted by global regulators, including the FDA and EMA.'

factnew Datavant was named the #1 2026 Best in KLAS winner in both Risk Adjustment: Coding, Retrieval & Compliance Solutions (90.5/100, A-) and Outsourced Coding (94.9/100), and placed 2nd in Release of Information (93.6) — its second consecutive year of payer-business KLAS recognition, announced 2026-02-04.

factnew Datavant's risk-adjustment franchise is built on Apixio (connected-care + value-based-care business, acquired Sept 2024), now sold as the Datavant Clinical Insights Platform (launched March 2025; Apixio brand sunset) for health plans and risk-bearing providers — codes 4.5M charts annually at 98% accuracy with up to 50% coding-cost reduction.

factnew Datavant is acquiring EHR/clinical DEPTH through partnerships rather than ownership: the Lighten Platforms partnership (2026-05-18) pipes Lighten's regulatory-grade, AI-curated unstructured-EHR datasets directly into Datavant's RWE analytics platform for epidemiology, natural-history, comparative-effectiveness and label-expansion studies.

factnew Labcorp launched an AI-powered real-world-data platform built with AWS and Datavant (2026-04-14), starting with Alzheimer's and expanding through 2026 to inflammatory, cardiometabolic, women's-health and oncology data — Labcorp supplies data, AWS the analytics, Datavant the privacy-preserving connectivity (Labcorp is also a Datavant investor).

factnew Thermo Fisher's PPD clinical-research business signed a strategic collaboration with Datavant (2026-02-11) embedding Datavant's encrypted-token technology across PPD clinical research, CorEvitas registries and Evidera, for RWD enrichment of randomized trials — though Thermo Fisher/PPD also partners with HealthVerity, confirming Datavant's connectivity is bought non-exclusively.

factnew Datavant remains New Mountain Capital-controlled and ownership stays fluid: a ~$32B buyout led by ex-New Mountain executive Matt Holt's vehicle Thoreau (bundling Datavant with Swoop, Machinify, Smarter Technologies and Office Ally) collapsed when New Mountain ended talks in early 2026 — watch for another process. Roivant and Labcorp are among backers (independently corroborated by their SEC filings naming Datavant).

factnew Datavant opened a Global R&D Centre in Galway, Ireland (Bonham Quay campus, IDA Ireland-backed), targeting up to 125 engineering jobs by end-2027 and already at 100 hires, explicitly focused on building its life-sciences technology roadmap and enterprise integration — adding to an existing Barcelona engineering hub (per current postings), an international build-out aimed at the RWE/life-sciences product.

factnew Datavant committed to the CMS Aligned Network Framework to accelerate interoperability and secure patient-record exchange, reinforcing its 'rails everyone rides' infrastructure position (alongside its TEFCA/record-exchange footprint) even as it moves up-stack into analytics and risk adjustment.

factnew Datavant-linked data and Aetion methods underpin a steady regulatory/pharmacoepi publication base — 23 Datavant-tagged PubMed papers and 7 NIH RePORTER-funded projects since Jan 2025, spanning RWD safety-signal detection, EHR/claims information-bias methods, and a Science perspective on governing RWD as a public utility — a credibility signal Inovalon's life-sciences RWD must match.

factnew Demand-side signal: Datavant reported receiving roughly 5x more AI-governance questionnaires from customers in 2025 than in 2024, indicating pharma/payer buyers are escalating diligence on AI governance and data provenance — a purchasing-criteria shift any RWD vendor (Inovalon included) must be ready to answer.

factnew Demand-side signal: Datavant reported receiving roughly 5x more AI-governance questionnaires from customers in 2025 than in 2024, indicating pharma/payer buyers are escalating diligence on AI governance and data provenance — a purchasing-criteria shift any RWD vendor (Inovalon included) must be ready to answer.